Contact this trialFirst, we need to learn more about you.
Virus Therapy
CMP-001 + Nivolumab for Melanoma
Recruiting1 awardPhase 2 & 3
Los Angeles, California
This trial is studying CMP-001 in combination with nivolumab compared to nivolumab monotherapy as a first-line treatment for unresectable or metastatic melanoma. The primary objective of Phase 2 of the study is to determine the confirmed ORR for treatment with CMP-001/nivolumab vs nivolumab monotherapy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service